Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research.

Autor:	Ibanez L; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Liu M; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Beric A; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Timsina J; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Kohlfeld P; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Bergmann K; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Lowery J; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Sykora N; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Sanchez-Montejo B; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Brock W; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Budde JP; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Bateman RJ; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.; Hope Center for Neurologic Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.; The Tracy Family SILQ Center, Washington University School of Medicine, St. Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA., Barthelemy N; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.; The Tracy Family SILQ Center, Washington University School of Medicine, St. Louis, Missouri, USA., Schindler SE; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.; Hope Center for Neurologic Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA., Holtzman DM; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.; Hope Center for Neurologic Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA., Benzinger TLS; Hope Center for Neurologic Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.; Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA., Xiong C; Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA., Tarawneh R; Department of Neurology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA., Moulder K; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA., Morris JC; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA., Sung YJ; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA., Cruchaga C; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA.; Hope Center for Neurologic Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.; Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Nov 22. Date of Electronic Publication: 2024 Nov 22.
DOI:	10.1002/alz.14413
Abstrakt:	Introduction: In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes. Methods: We compared AD-relevant biomarkers included in the NULISA against validated assays in cerebrospinal fluid (CSF) and plasma. Results: CSF measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p-tau217 performance is similar to that reported with other technologies when predicting amyloidosis. Other biomarkers show a wide range of correlation values depending on the fluid and the platform. Discussion: The NULISA multiplexed platform produces reliable results for established biomarkers in CSF that are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume. Highlights: We tested the novel technology NUcleic acid Linked Immuno-Sandwich Assay (NULISA) in the dementia research setting. NULISA multiplexed platform produces reliable results for established and emerging biomarkers using minimal sample volume. Cerebrospinal fluid measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p-tau217 performance is similar to that reported with other technologies when predicting amyloidosis. NULISA measures are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume. (© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text